Royal Bank Of Canada Issues Positive Forecast for Oxford Biomedica (LON:OXB) Stock Price

Key Points

• Royal Bank of Canada has increased the price target for Oxford Biomedica from GBX 800 to GBX 930, indicating a potential upside of 68.17% from the stock's previous close.
• The company currently holds a consensus rating of "Moderate Buy" with an average price target of GBX 540.25, according to MarketBeat.
• In insider trading news, Dame Kay Davies sold 4,563 shares for a total of £22,815, while Heather Preston acquired 11,389 shares valued at £36,900.36.

Oxford Biomedica (LON:OXB - Free Report) had its price target upped by Royal Bank Of Canada from GBX 800 to GBX 930 in a research note issued to investors on Tuesday morning, Marketbeat reports. Royal Bank Of Canada currently has an outperform rating on the biopharmaceutical company's stock.

Several other analysts have also recently commented on the stock. JPMorgan Chase & Co. reduced their target price on shares of Oxford Biomedica from GBX 490 to GBX 400 and set a "neutral" rating for the company in a research note on Tuesday, July 15th. Peel Hunt restated a "buy" rating and issued a GBX 451 target price on shares of Oxford Biomedica in a research note on Friday, August 1st. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of GBX 540.25.

Oxford Biomedica Stock Performance

Shares of OXB stock traded up GBX 14 during mid-day trading on Tuesday, hitting GBX 571. The stock had a trading volume of 411,274 shares, compared to its average volume of 231,054. Oxford Biomedica has a fifty-two week low of GBX 232.50 and a fifty-two week high of GBX 578.16. The firm has a market cap of £606.98 million, a PE ratio of -4.24 and a beta of 1.09. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67. The company's 50-day simple moving average is GBX 410.16 and its 200-day simple moving average is GBX 343.95.

Insider Buying and Selling at Oxford Biomedica

In other Oxford Biomedica news, insider Dame Kay Davies sold 4,563 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of GBX 500, for a total transaction of £22,815. Also, insider Heather Preston bought 11,389 shares of the company's stock in a transaction on Tuesday, June 17th. The shares were acquired at an average price of GBX 324 per share, with a total value of £36,900.36. 21.17% of the stock is currently owned by insiders.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.